Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma

Annals of Hematology

Volumn 88, Issue 2, 2009, Pages 133-139

  Fischer, Lars ^a   Korfel, Agnieszka ^a   Kiewe, Philipp ^a   Neumann, Martin ^a   Jahnke, Kristoph ^a   Thiel, Eckhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CNS lymphoma; Ifosfamide; Methotrexate; Neoplastic meningitis

Indexed keywords

CARMUSTINE; CYTARABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; THIOTEPA; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INFECTION; LEUKOPENIA; LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SYMPTOMATOLOGY; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 58149086076     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0575-8     Document Type: Article

References (32)

1. Bokstein F, Lossos A, Siegal T (1998) Leptomeningeal metastases from solid tumors: A comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82:1756-1763. doi: 10.1002/ (SICI)1097-0142(19980501)82:9<1764::AID-CNCR24>3.0.CO;2-1
2. Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110-3116
3. Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394-3402
4. Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11:561-569
5. Bokstein F, Lossos A, Lossos IS et al (2002) Central nervous system relapse of systemic non-Hodgkin's lymphoma: Results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 43:587-593. doi: 10.1080/10428190290012092
6. Bollen EL, Brouwer RE, Hamers S et al (1997) Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 54:854-859
7. Lagerwaard FJ, Levendag PC, Nowak PJ et al (1999) Identification of prognostic factors in patients with brain metastases: A review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795-803. doi: 10.1016/ S0360-3016(98)00442-8
8. van Besien K, Ha CS, Murphy S et al (1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:1178-1184
9. Blaney SM, Poplack DG (1996) Pharmacologic strategies for the treatment of meningeal malignancy. Invest New Drugs 14:69-85. doi: 10.1007/ BF00173684
10. Hiraga S, Arita N, Ohnishi T et al (1999) Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91:221-230
11. Tetef ML, Margolin KA, Doroshow JH et al (2000) Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46:19-26. doi: 10.1007/s002800000118
12. Yule SM, Price L, Pearson AD et al (1997) Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res 3:1985-1992
13. Abrey LE, Batchelor TT, Ferreri AJ et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043. doi: 10.1200/JCO.2005.13.524
14. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
15. Boogerd W, Hart AA, van der Sande JJ et al (1991) Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67:1685-1695. doi: 10.1002/ 1097-0142(19910315)67:6<1685::AID-CNCR2820670635>3.0.CO;2-M
16. Herrlinger U, Forschler H, Kuker W et al (2004) Leptomeningeal metastasis: Survival and prognostic factors in 155 patients. J Neurol Sci 223:167-178. doi: 10.1016/j.jns.2004.05.008
17. Siegal T, Lossos A, Pfeffer MR (1994) Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 44:1463-1469
18. Glantz MJ, Cole BF, Recht L et al (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol 16:1561-1567
19. Lassman AB, Abrey LE, Shah GD et al (2006) Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 78:255-260. doi: 10.1007/s11060-005-9044-6
20. Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM et al (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70:219-224. doi: 10.1034/j.1600-0609.2003.00045.x
21. Pels H, Schmidt-Wolf IG, Glasmacher A et al (2003) Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489-4495. doi: 10.1200/JCO.2003.04.056
22. Jahnke K, Wagner T, Bechrakis NE et al (2005) Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma. Ann Oncol 16:1974-1978. doi: 10.1093/annonc/mdi409
23. Ferreri AJ, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266-272. doi: 10.1200/JCO.2003.09.139
24. Shipp MA (1997) Can we improve upon the international index? Ann Oncol 8(Suppl 1):43-47. doi: 10.1023/A:1008245615520
25. Alvarnas JC, Negrin RS, Horning SJ et al (2000) High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6:352-358. doi: 10.1016/S1083-8791(00)70060-7
26. Jahnke K, Thiel E, Martus P et al (2006) Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 85:45-50. doi: 10.1007/ s00277-005-1096-3
27. Hottinger AF, DeAngelis LM, Yahalom J et al (2007) Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69:1178-1182. doi: 10.1212/01.wnl.0000276986.19602.c1
28. Fischer L, Thiel E, Klasen HA et al (2004) Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 62:1885-1887
29. Herrlinger U, Kuker W, Uhl M et al (2005) NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: Final report. Ann Neurol 57:843-847. doi: 10.1002/ana.20495
30. Omuro AM, Ben Porat LS, Panageas KS et al (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62:1595-1600. doi: 10.1001/archneur.62.10.1595
31. Reni M, Ferreri AJ (2001) Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 80(Suppl 3):B113-B117. doi: 10.1007/s002770000230
32. Blay JY, Conroy T, Chevreau C et al (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16:864-871